Citius Pharmaceuticals annual shares outstanding
2010
2011
2012
2012
2013
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Citius Pharmaceuticals Shares Outstanding History (CTXR)
Citius Pharmaceuticals reported 18.1M shares outstanding at the end of fiscal 2025.
View full Citius Pharmaceuticals company overviewCitius Pharmaceuticals annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-09-30 | 18.1M | 10.8M | +149.31% |
| 2024 | 2024-09-30 | 7.2M | 892,872 | +14.05% |
| 2023 | 2023-09-30 | 6.4M | 505,925.8 | +8.65% |
| 2022 | 2022-09-30 | 5.8M | 9,268.04 | +0.16% |
| 2021 | 2021-09-30 | 5.8M | 3.6M | +162.66% |
| 2020 | 2020-09-30 | 2.2M | 1.1M | +92.11% |
| 2019 | 2019-09-30 | 1.2M | 509,268.08 | +78.60% |
| 2018 | 2018-09-30 | 647,951.64 | 314,117.88 | +94.09% |
| 2017 | 2017-09-30 | 333,833.76 | 138,798.92 | +71.17% |
| 2016 | 2016-09-30 | 195,034.84 | 104,053.811 | +114.37% |
| 2015 | 2015-09-30 | 90,981.029 | 10,913.576 | +13.63% |
| 2014 | 2014-09-30 | 80,067.453 | 32,067.453 | +66.81% |
| 2013 · Dec 31 | 2013-12-31 | 47,352.888 | −647.112 | −1.35% |
| 2013 · Sep 30 | 2013-09-30 | 48,000 | 0 | 0.00% |
| 2012 · Dec 31 | 2012-12-31 | 48,000 | — | — |
| 2012 · Sep 30 | 2012-09-30 | 48,000 | 0 | 0.00% |
| 2011 | 2011-09-30 | 48,000 | 0 | 0.00% |
| 2010 | 2010-09-30 | 48,000 | — | — |
Citius Pharmaceuticals quarterly shares outstanding
Q4.10
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q4.12
Q1.13
Q2.13
Q4.13
Q4.13
Q1.14
Q2.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-06-30 | 27.5M | 13.0M | +89.65% |
| Q2 2026 | 2026-03-31 | 22.4M | 13.6M | +155.42% |
| Q1 2026 | 2025-12-31 | 22.4M | 14.6M | +189.58% |
| Q4 2025 | 2025-09-30 | 18.1M | 10.8M | +149.31% |
| Q3 2025 | 2025-06-30 | 14.5M | 7.2M | +100.24% |
| Q2 2025 | 2025-03-31 | 8.8M | 2.4M | +37.66% |
| Q1 2025 | 2024-12-31 | 7.7M | 1.4M | +21.52% |
| Q4 2024 | 2024-09-30 | 7.2M | 892,872 | +14.05% |
| Q3 2024 | 2024-06-30 | 7.2M | 874,704.36 | +13.77% |
| Q2 2024 | 2024-03-31 | 6.4M | 509,479.36 | +8.70% |
| Q1 2024 | 2023-12-31 | 6.4M | 510,217.84 | +8.72% |
| Q4 2023 | 2023-09-30 | 6.4M | 505,925.8 | +8.65% |
| Q3 2023 | 2023-06-30 | 6.4M | 509,126.72 | +8.71% |
| Q2 2023 | 2023-03-31 | 5.9M | 9,126.68 | +0.16% |
| Q1 2023 | 2022-12-31 | 5.8M | 7,260 | +0.12% |
| Q4 2022 | 2022-09-30 | 5.8M | 9,268.04 | +0.16% |
| Q3 2022 | 2022-06-30 | 5.8M | 6,008.04 | +0.10% |
| Q2 2022 | 2022-03-31 | 5.8M | 457,136.44 | +8.48% |
| Q1 2022 | 2021-12-31 | 5.8M | 3.6M | +162.75% |
| Q4 2021 | 2021-09-30 | 5.8M | 3.6M | +162.66% |
| Q3 2021 | 2021-06-30 | 5.8M | 4.0M | +215.18% |
| Q2 2021 | 2021-03-31 | 5.4M | 3.9M | +253.75% |
| Q1 2021 | 2020-12-31 | 2.2M | 1.0M | +84.17% |
| Q4 2020 | 2020-09-30 | 2.2M | 1.1M | +92.11% |
| Q3 2020 | 2020-06-30 | 1.9M | 969,620.68 | +109.81% |
| Q2 2020 | 2020-03-31 | 1.5M | 777,308.08 | +104.22% |
| Q1 2020 | 2019-12-31 | 1.2M | 495,155.32 | +69.55% |
| Q4 2019 | 2019-09-30 | 1.2M | 509,268.08 | +78.60% |
| Q3 2019 | 2019-06-30 | 883,031.24 | 455,942.36 | +106.76% |
| Q2 2019 | 2019-03-31 | 745,814.4 | 319,125.52 | +74.79% |
| Q1 2019 | 2018-12-31 | 711,951.64 | 312,930.92 | +78.42% |
| Q4 2018 | 2018-09-30 | 647,951.64 | 314,117.88 | +94.09% |
| Q3 2018 | 2018-06-30 | 427,088.88 | 224,799 | +111.13% |
| Q2 2018 | 2018-03-31 | 426,688.88 | 225,344.235 | +111.92% |
| Q1 2018 | 2017-12-31 | 399,020.72 | 201,385.893 | +101.90% |
| Q4 2017 | 2017-09-30 | 333,833.76 | 138,798.92 | +71.17% |
| Q3 2017 | 2017-06-30 | 202,289.88 | 7,521.72 | +3.86% |
| Q2 2017 | 2017-03-31 | 201,344.645 | 11,643.2 | +6.14% |
| Q1 2017 | 2016-12-31 | 197,634.827 | 105,098.24 | +113.57% |
| Q4 2016 | 2016-09-30 | 195,034.84 | 104,053.811 | +114.37% |
| Q3 2016 | 2016-06-30 | 194,768.16 | 106,164.931 | +119.82% |
| Q2 2016 | 2016-03-31 | 189,701.445 | 105,485.872 | +125.26% |
| Q1 2016 | 2015-12-31 | 92,536.587 | 9,654.347 | +11.65% |
| Q4 2015 | 2015-09-30 | 90,981.029 | 10,913.576 | +13.63% |
| Q3 2015 | 2015-06-30 | 88,603.229 | 40,603.229 | +84.59% |
| Q2 2015 | 2015-03-31 | 84,215.573 | 36,215.573 | +75.45% |
| Q1 2015 | 2014-12-31 | 82,882.24 | 35,529.352 | +75.03% |
| Q4 2014 | 2014-09-30 | 80,067.453 | 32,067.453 | +66.81% |
| Q2 2014 | 2014-06-30 | 48,000 | 0 | 0.00% |
| Q1 2014 | 2014-03-31 | 48,000 | 0 | 0.00% |
| Q4 2013 · Dec 31 | 2013-12-31 | 47,352.888 | −647.112 | −1.35% |
| Q4 2013 · Sep 30 | 2013-09-30 | 48,000 | 0 | 0.00% |
| Q2 2013 | 2013-06-30 | 48,000 | 0 | 0.00% |
| Q1 2013 | 2013-03-31 | 48,000 | 0 | 0.00% |
| Q4 2012 · Dec 31 | 2012-12-31 | 48,000 | 0 | 0.00% |
| Q4 2012 · Sep 30 | 2012-09-30 | 48,000 | 0 | 0.00% |
| Q3 2012 | 2012-06-30 | 48,000 | 0 | 0.00% |
| Q2 2012 | 2012-03-31 | 48,000 | — | — |
| Q1 2012 | 2011-12-31 | 48,000 | — | — |
| Q4 2011 | 2011-09-30 | 48,000 | 0 | 0.00% |
| Q3 2011 | 2011-06-30 | 48,000 | — | — |
| Q4 2010 | 2010-09-30 | 48,000 | — | — |
Citius Pharmaceuticals shares outstanding trends
Over the last five fiscal years, Citius Pharmaceuticals's shares outstanding moved from 2.2M to 18.1M, a change of 15.8M. The latest reported quarter, Q3 2026, shows 27.5M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Citius Pharmaceuticals source filings ↗